GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Short-Term Debt & Capital Lease Obligation

Vivesto AB (Vivesto AB) Short-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Vivesto AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Vivesto AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.


Vivesto AB Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Vivesto AB's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Short-Term Debt & Capital Lease Obligation Chart

Vivesto AB Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.96 8.52 0.58 0.29 -

Vivesto AB Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.30 0.27 0.24 -

Vivesto AB Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Vivesto AB Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB (Vivesto AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Short-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB (Vivesto AB) Headlines

From GuruFocus